指南与共识外周血管技术与安全

ANCA相关性血管炎的诊断与治疗:德国风湿病学会等S3级指南短版

[Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), Germa
指南 / 共识 · Z Rheumatol · 2025-04-02

该S3级指南由德国风湿病学会等多学会联合制定,将2017年S1级指南升级为S3级,是德国首部S3级ANCA相关性血管炎诊疗指南。指南强调患者应尽快诊断并根据当前研究证据接受免疫抑制剂和生物制剂治疗,近年治疗进展使基于证据的治疗成为可能。

要点

  • ANCA相关性血管炎为罕见病,病程可能严重,患者应尽快诊断。
  • 近年治疗进展使免疫抑制剂和生物制剂的大体循证治疗成为可能。
  • 指南由S1级(2017年)升级为S3级,为德国首部S3级ANCA相关性血管炎指南。

核心结论

  • ANCA相关性血管炎患者应尽快诊断并根据当前研究证据接受合适治疗,近年进展使免疫抑制剂和生物制剂的循证治疗成为可能。

研究设计与样本

  • 德国风湿病学会等多家学会联合制定的S3级指南,由2017年S1级指南升级而来,为德国首部S3级ANCA相关性血管炎诊疗指南。

临床应用与阅片要点

  • 原文指出患者应尽快诊断并根据当前研究证据接受合适治疗。
  • 原文指出免疫抑制剂和生物制剂的大体循证治疗已成为可能。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA) is a rare disease with a potentially severe course. Affected patients should be diagnosed as quickly as possible and given suitable treatment according to the current study situation. Considerable progress has been made in the treatment of this disease in recent years, so that a largely evidence-based therapy with immunosuppressants and biologics is now possible. The guideline on the diagnosis and treatment of ANCA-associated vasculitis was raised from S1 level (2017) to S3 level. This guideline is the first German guideline on the diagnosis and treatment of ANCA-associated vasculitis at S3 level.

Die mit Anti-Neutrophilen zytoplasmatischen Antikörpern (ANCA) assoziierten Vaskulitiden (AAV) sind eine seltene Erkrankung mit potenziell schwerem Verlauf. Betroffene Patienten sollten möglichst schnell diagnostiziert und gemäß aktueller Studienlage einer geeigneten Therapie zugeführt werden. In der Behandlung der AAV gab es in den letzten Jahren beachtliche Fortschritte, so dass mittlerweile eine weitgehend evidenzbasierte Therapie mittels Immunsuppressiva und Biologika möglich ist. Die Leitlinie zur Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden wurde mit dieser Leitlinie von S1-Niveau (2017) auf S3-Niveau angehoben. Diese Leitlinie ist die erste deutsche Leitlinie zur Diagnostik und Therapie der AAV auf S3-Niveau.

来源:Z Rheumatol,查看原文。版权归原作者所有。

引用

  1. Holle JU, Kubacki T, Aries P, et al. [Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]. Z Rheumatol. 2025. PMID: 40172651. doi:10.1007/s00393-024-01596-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。